Division of Public Oral Health, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South Africa.
Int Dent J. 2011 Aug;61(4):179-92. doi: 10.1111/j.1875-595X.2011.00055.x.
To investigate extent and quality of current systematic review evidence regarding: powered toothbrushes, triclosan toothpaste, essential oil mouthwashes, xylitol chewing gum.
Five databases were searched for systematic reviews until 13 November 2010.
relevant to topic, systematic review according to title and/or abstract, published in English. Article exclusion criteria were based on QUOROM recommendations for the reporting of systematic review methods. Systematic review quality was judged using the AMSTAR tool. All trials included by reviews were assessed for selection bias.
119 articles were found, of which 11 systematic reviews were included. Of these, six were excluded and five accepted: one for triclosan toothpaste; one for xylitol chewing gum; two for powered toothbrushes; one for essential oil mouthwashes. AMSTAR scores: triclosan toothpaste 7; powered toothbrushes 9 and 11; xylitol chewing gum 9; essential oil mouthwashes 8. In total, 75 (out of 76) reviewed trials were identified. In-depth assessment showed a high risk of selection bias for all trials.
The extent of available systematic review evidence is low. Although the few identified systematic reviews could be rated as of medium and high quality, the validity of their conclusions needs to be treated with caution, owing to high risk of selection bias in the reviewed trials. High quality randomised control trials are needed in order to provide convincing evidence regarding true clinical efficacy.
调查当前关于以下方面的系统评价证据的范围和质量:电动牙刷、三氯生牙膏、精油漱口水、木糖醇口香糖。
截至 2010 年 11 月 13 日,在五个数据库中搜索系统评价。
与主题相关,根据标题和/或摘要判断为系统评价,以英文发表。文章排除标准基于 QUOROM 对系统评价方法报告的建议。使用 AMSTAR 工具评估系统评价质量。对所有纳入综述的试验进行选择性偏倚评估。
共发现 119 篇文章,其中纳入 11 篇系统评价。其中,6 篇被排除,5 篇被接受:1 篇关于三氯生牙膏;1 篇关于木糖醇口香糖;2 篇关于电动牙刷;1 篇关于精油漱口水。AMSTAR 评分:三氯生牙膏 7 分;电动牙刷 9 分和 11 分;木糖醇口香糖 9 分;精油漱口水 8 分。总共,有 76 项综述中提到的试验得到了确认。深入评估显示,所有试验都存在高度的选择性偏倚风险。
现有的系统评价证据范围有限。尽管少数已确定的系统评价可被评为中高质量,但由于纳入的试验存在高度的选择性偏倚风险,其结论的有效性需要谨慎对待。需要高质量的随机对照试验,才能提供关于真实临床疗效的确凿证据。